Raber MN - Search Results

1

Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer.

Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN, et al. Murphy WK, et al. Among authors: raber mn. J Natl Cancer Inst. 1993 Mar 3;85(5):384-8. doi: 10.1093/jnci/85.5.384. J Natl Cancer Inst. 1993. PMID: 8094466 Clinical Trial.

2

Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose-limiting.

Shin DM, Holoye PY, Murphy WK, Forman A, Papasozomenos SC, Hong WK, Raber M. Shin DM, et al. Cancer Chemother Pharmacol. 1991;29(2):145-9. doi: 10.1007/BF00687325. Cancer Chemother Pharmacol. 1991. PMID: 1662119 Clinical Trial.

3

Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma.

Fossella FV, Winn RJ, Holoye PY, Hallinan B, Raber MN, Hoelzer K, Young JA, Readling J, Bowers B, Hong WK. Fossella FV, et al. Among authors: raber mn. Invest New Drugs. 1992 Nov;10(4):331-5. doi: 10.1007/BF00944191. Invest New Drugs. 1992. PMID: 1336771 Clinical Trial.

4

Phase II trial of intravenous 6-thioguanine for unresectable or metastatic non-small cell bronchogenic carcinoma.

Fossella FV, Winn RJ, Holoye PY, Raber MN, Holden L, Belt R, Allen H, Hallinan B, Harper K. Fossella FV, et al. Among authors: raber mn. Invest New Drugs. 1991 Nov;9(4):375-6. doi: 10.1007/BF00183586. Invest New Drugs. 1991. PMID: 1666631 Clinical Trial. No abstract available.

5

Ifosfamide with mesna uroprotection in the management of lung cancer.

Holoye PY, Glisson BS, Lee JS, Dhingra HM, Murphy WK, Umsawasdi T, Levy JK, Jeffries D, Raber MN, Hong WK. Holoye PY, et al. Among authors: raber mn. Am J Clin Oncol. 1990 Apr;13(2):148-55. doi: 10.1097/00000421-199004000-00012. Am J Clin Oncol. 1990. PMID: 2156418

6

Phase II clinical trial of didemnin B in previously treated small cell lung cancer.

Shin DM, Holoye PY, Forman A, Winn R, Perez-Soler R, Dakhil S, Rosenthal J, Raber MN, Hong WK. Shin DM, et al. Among authors: raber mn. Invest New Drugs. 1994;12(3):243-9. doi: 10.1007/BF00873966. Invest New Drugs. 1994. PMID: 7896544 Review.

7

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.

Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Kemp BL, Lee JJ, Kane J, Robinson RA, Lippman SM, Kurie JM, Huber MH, Raber MN, Hong WK. Perez-Soler R, et al. Among authors: raber mn. J Clin Oncol. 1996 Feb;14(2):503-13. doi: 10.1200/JCO.1996.14.2.503. J Clin Oncol. 1996. PMID: 8636764 Clinical Trial.

8

Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN. Holmes FA, et al. Among authors: raber mn. J Natl Cancer Inst. 1991 Dec 18;83(24):1797-805. doi: 10.1093/jnci/83.24.1797-a. J Natl Cancer Inst. 1991. PMID: 1683908 Clinical Trial.

9

Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma.

Dhingra HM, Murphy WK, Winn RJ, Raber MN, Hong WK. Dhingra HM, et al. Among authors: raber mn. Invest New Drugs. 1991 Feb;9(1):69-72. doi: 10.1007/BF00194548. Invest New Drugs. 1991. PMID: 1709153 Clinical Trial. No abstract available.

10

Phase II clinical trial of 4'-O-tetrahydropyranyl-adriamycin (THP-adriamycin) in recurrent squamous cell carcinoma of the head and neck.

Shin DM, Kramer AM, Dimery IW, Raber MN, Ewer M, Hong WK. Shin DM, et al. Among authors: raber mn. Invest New Drugs. 1991 Feb;9(1):89-91. doi: 10.1007/BF00194554. Invest New Drugs. 1991. PMID: 2026488 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

83 results

Search Page

Filters